Theratechnologies Appoints New Board Member
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ:
THTX), a biopharmaceutical company focused on the development and
commercialization of innovative therapies, today announced the
appointment of Mr. Frank Holler as a new independent member to its
Board of Directors.
“The appointment of Frank Holler adds important
expertise and capabilities to the Board. Frank brings extensive
knowledge and experience in the North American capital markets and
has a well-recognized track record in the biotech industry having
been involved in the establishment and growth of four of Canada’s
most successful biopharmaceutical companies,” said Ms. Dawn
Svoronos, Chair of the Board, Theratechnologies Inc.
“On behalf of the Board of Directors at
Theratechnologies, it is my pleasure to welcome Frank. He arrives
at a crucial time in Theratechnologies’ history as the Company
continues to grow its commercial business globally and advance its
exciting pipeline, namely moving forward its lead Peptide-Drug
Conjugate, TH1902, through a Phase 1 clinical trial for the
potential treatment of solid tumors expressing the sortilin
receptor and advancing the development program for tesamorelin in
Nonalcoholic Steatohepatitis (NASH) in the general population.
Frank’s in-depth experience at growing shareholder value and strong
knowledge of the challenges and opportunities in the biotech
industry will be great assets for the Board,” added Ms.
About Frank HollerFrank A.
Holler is currently President & CEO of Ponderosa Capital Inc.
He previously served as Chairman & CEO of BC Advantage Funds
(VCC) Ltd., a venture capital firm investing in emerging technology
companies in British Columbia.
He also served as President and CEO of Xenon
Pharmaceuticals Inc. from 1999 to 2003 after having been President
and CEO of ID Biomedical Corporation from 1991 to 1998. In
addition, he was a founding director of Angiotech
Prior to working in biotechnology and
healthcare, Mr. Holler was a Vice-President of Investment Banking
with Merrill Lynch Canada and Wood Gundy Inc. (now CIBC World
Mr. Holler holds an MBA and BA (Economics) from
the University of British Columbia.
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical
company focused on the development and commercialization of
innovative therapies addressing unmet medical needs. Further
information about Theratechnologies is available on the Company's
website at www.theratech.com, on SEDAR at www.sedar.com and on
EDGAR at www.sec.gov.
This press release contains forward-looking statements and
forward-looking information, or, collectively, forward-looking
statements, within the meaning of applicable securities laws, that
are based on our management’s beliefs and assumptions and on
information currently available to our management. You can identify
forward-looking statements by terms such as "may", "will",
"should", "could", “would”, "outlook", "believe", "plan",
"envisage", "anticipate", "expect" and "estimate", or the negatives
of these terms, or variations of them. The forward-looking
statements contained in this press release include, but are not
limited to, statements regarding the growth of the commercial
business of the Company, the development of tesamorelin for the
potential treatment of NASH in the general population and the
development of TH1902 in a Phase 1 clinical trial for the potential
treatment of solid tumors expressing the sortilin receptor.
Forward-looking statements are based upon a
number of assumptions and include, but are not limited to, the
following: the development of tesamorelin for the potential
treatment of NASH in the general population and the development of
TH1902 will yield positive results and lead to new medicines being
approved for the treatment of NASH and the treatment of cancer,
respectively, and sales of our commercial products in the HIV field
will grow overtime.
Forward-looking statements are subject to a
variety of risks and uncertainties, many of which are beyond our
control that could cause our actual results to differ materially
from those that are disclosed in or implied by the forward-looking
statements contained in this press release. These risks and
uncertainty include the risk that (i) the Covid-19 pandemic
materially adversely affect our business plan and activities, (ii)
sales of our commercial products do not grow overtime and may even
decrease, (iii) the recruitment of patients for the ongoing Phase 1
clinical trial and the planned Phase 3 clinical trial in NASH is
harder than expected leading to delays in completing them or
leading to a suspension or halt for any of them, (iv) negative
results ensue from those trials, and (v) EGRIFTA SV® and/or
Trogarzo® are subject to unknown serious adverse events which could
lead to product withdrawal from the market or blackbox
We refer potential investors to the "Risk
Factors" section of our annual information form dated February 24,
2021 available on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov as an exhibit to our report on Form 40-F dated February
25, 2021 under Theratechnologies’ public filings for additional
risks regarding the conduct of our business and Theratechnologies.
The reader is cautioned to consider these and other risks and
uncertainties carefully and not to put undue reliance on
forward-looking statements. Forward-looking statements reflect
current expectations regarding future events and speak only as of
the date of this press release and represent our expectations as of
We undertake no obligation to update or revise
the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise, except as may be required by applicable law.
For media inquiries:Denis BoucherVice President, Communications
and Corporate Affairs514email@example.com
For investor inquiries:Leah GibsonSenior Director, Investor
Historical Stock Chart
From Sep 2021 to Oct 2021
Historical Stock Chart
From Oct 2020 to Oct 2021